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Abstract 
Adhesion receptors are transmembrane proteins that mediate cell-cell and cell-matrix 
communications. In addition to their adhesive role in maintaining islet architecture, they are also 
important for promoting islet cell survival, proliferation and secretory function. Their capacity for 
improving -cell mass and insulin secretion suggest that they may be suitable targets for 
pharmacological intervention, and their interactions with extracellular matrix proteins hold promise 
in improving islet transplantation outcomes. In this review, we have focused on integrins, cadherins 
and adhesion GPCRs, and highlight recent advances in their roles in islet function and discuss 
whether they could be targeted for diabetes therapy. 
 
Highlights 
• Adhesion receptors expressed by islets include integrins, cadherins and adhesion GPCRs. 
• Endogenous ligands of adhesion receptors are mainly proteins of the extracellular matrix. 
• Adhesion receptors are essential for maintaining islet architecture, survival and function. 
• Islet adhesion receptors are unexplored targets for type 2 diabetes therapy and they also 
offer potential for optimising cell replacement therapy for type 1 diabetes. 
 
Introduction 
Islets of Langerhans are heterogeneous cell clusters in the pancreas, consisting mainly of insulin-
secreting β-cells, glucagon-secreting α-cells and somatostatin-secreting δ-cells, and there are also 
minority endocrine cell types that express the peptides pancreatic polypeptide and ghrelin. These 
cells are arranged in compact three-dimensional clusters and they work synchronously to maintain 
euglycemia. Earlier observations in which isolated β-cells secreted less insulin than -cells within 
intact islets point to the importance of intercellular contacts and cellular organisation in islet 
function [1]. Moreover, there are several reports that islets exposed to extracellular matrix (ECM) 
proteins exhibit increased survival and improved insulin secretion [2–5], which is suggestive of an 
important role for islet-matrix interactions in appropriate regulation of glucose homeostasis.  
 
The ECM consists of a fibrous mesh that contains proteins such as collagens, elastins, fibronectins 
and laminins, which provide structural support to cells and facilitate cellular elasticity, motility and 
adhesion. These ECM proteins can regulate cellular function by interaction with families of cell 
surface adhesion receptors that include integrins, cadherins and adhesion G-protein-coupled 
receptors (GPCRs). Islets express members of these adhesion receptors, which allow them to sense 
signals from the ECM and the islet microenvironment (Figure 1). This is of potential therapeutic 
interest for diabetes since drugs targeting adhesion receptors are in current use or are undergoing 
clinical trials to treat diseases such as multiple sclerosis, inflammatory bowel disease, cancer and 
asthma (Table 1) [6]. However, despite the important roles that adhesion receptors play in islet 
function they have not yet been investigated as potential targets for diabetes therapy. This article 
reviews recently published data on islet adhesion receptors and considers the therapeutic 
implications for diabetes.  
 
Diabetes epidemic: a case for additional therapeutic options 
Diabetes is rapidly becoming a global epidemic, with a current incidence of 425 million people 
worldwide (International Diabetes Federation; URL: https://www.idf.org/). With the current trend of 
globalisation, physical inactivity, obesity and increased longevity, diabetes will continue to have 
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significant human and financial consequences for the foreseable future: the number of people 
affected is predicted to increase by 48% by 2045 (International Diabetes Federation; URL: 
https://www.idf.org/) and the global cost of diabetes is set to rise to $2.5 trillion by 2030 [7]. There 
are currently a range of drugs available to treat type 2 diabetes (T2D), which accounts for 
approximately 90% of all diabetes cases, but approximately 50% of younger T2D patients cannot 
achieve their glycaemic target with the available drugs despite a good history of adherence [8]. 
Potential T2D therapies targeting GPCRs such as GPR40 and GPR119 have largely had unsatisfactory 
outcomes in clinical trials [9], and there is still a pressing need to identify additional therapeutic 
targets that may be used for appropriate glucoregulation in T2D.  
 
Islet adhesion receptors 
Adhesion receptors are plasma membrane proteins consisting of a ‘sticky’ extracellular domain, a 
transmembrane component and a cytosolic terminal domain, and the adhesion receptor superfamily 
consists of integrins, cadherins, immunoglobulin-like cell adhesion molecules, selectins and the more 
recently described adhesion GPCRs (aGPCRs). Selectins are not included in this short review because 
they are not expressed by islets per se, but by infiltrating lymphocytes in type 1 diabetes (T1D) [10].  
 
Defective communication between islet endocrine cells has deleterious consequences and 
contributes to the islet dysfunctions seen in T2D and neonatal diabetes mellitus [11, 12]. In addition, 
impaired islet function has been observed following deletion or inhibition of adhesion receptors. For 
example, reduced β1 integrin expression in islets results in impaired glucose tolerance and 
reductions in insulin secretion and islet mass [13], while inhibition of E-cadherin prevents the 
formation of pseudoislets, which are -cell clusters that have been configured to resemble native 
islets and show improved insulin secretion compared to dispersed cells [14]. All adhesion receptors 
are involved in cell-cell or cell-ECM interactions. It is known that the ECM plays a key role in islet 
differentiation and maintenance of a mature phenotype, since ECM collagen gene deletion in mice 
leads to reduced islet mass and impaired glucose-induced insulin secretion [15]. Additional studies 
have established the importance of ECM in islet survival, insulin secretion and proliferation [16–18], 
and there is now a good understanding of the molecular receptors mediating these functions.  
 
Integrins 
Integrins are integral membrane glycoproteins that exist as heterodimers of - and -subunits, with 
at least 24 different heterodimers identified in mammals, formed from eighteen - and eight β- 
subunits [19]. Integrins bind to a range of ECM components with varying affinity. Thus, α1β1, α2β1, 
and α10β1 preferentially bind to multiple collagen subunits, 51 binds to fibronectin, while α6β1 
and β4 interact with laminins [4, 20, 21]. There are at least five integrin heterodimers in islets (Table 
2), with rodent islets expressing α3, β1 and β4 integrin subunits [22], while human islets express α3, 
α5, αv, β1 and β5 subunits [23, 24]. Integrins have been implicated in β-cell processes such as 
differentiation, expansion, migration, survival and function [25–29] and they also participate in 
pancreas development by regulating morphogenesis, adhesion and migration of progenitor cells [25, 
26, 28].  
 
Integrin over-expression has been observed in the retina of people with long term diabetes [30], but 
there is currently no information on the expression pattern of integrins in islets from people with 
T2D. The multiplicity of integrin subunits and promiscuity in ligand binding has thus far confounded 
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attempts to translate the understanding of -cell integrin-ECM interactions into novel therapeutic 
targets. In addition, integrin-based therapies for T2D would require integrin activation to optimise -
cell mass and function, which could have deleterious effects as some integrin family members are 
up-regulated in cancer where they promote invasion and progression of metastasis. Drugs that 
antagonise integrin function, mainly by inhibiting heterodimers consisting of 4, 5 and 1 subunits, 
have been used in clinical trials for the treatment of cancers (Table 1), suggesting that integrin-based 
agonist therapies for T2D would only be feasible if they could be targeted to non-4/5-1 islet cell 
heterodimers. The observation that 31 integrins are abundantly expressed by islet cells [22] may 
provide some specificity, since this heterodimer is not currently targeted for cancer therapies. 
   
Cadherins 
Cadherins are calcium-dependent transmembrane glycoproteins that form adherens junctions 
between cells. Their extracellular N-terminal domain is used for homophilic adhesion by binding to 
cadherins on neighbouring cells and this is important in tissue morphogenesis. The intracellular 
domains of cadherins are linked to the actin cytoskeleton via - and -catenins [31], indicating that 
they can also initiate signalling rather than simply functioning to form stable adhesive complexes. 
The expression of some members of the classical cadherin subfamily such as epithelial (E-) and 
neural (N-) cadherins has been reported in human islets, whereas placental (P-) cadherin expression 
has not been detected [32]. N-cadherin is reported to be preferentially expressed by islet -cells 
while E-cadherin is expressed at similar levels by - and -cells [32].   
 
Cadherins play important roles in regulating islet structure and function. Thus, E-cadherin is 
necessary for the proper three-dimensional configuration of islets, and in the clustering of β-cells to 
form pseudoislets [14, 33] and it also influences various islet functions such as proliferation, survival 
and insulin secretion [34, 35]. Disruption of islet architecture by dispersal into single cells leads to 
poor secretory outcomes and increased apoptosis, but association of islet cells with E- and N-
cadherins reduces apoptosis in isolated human β-cells [32]. The specific involvement of E- and N-
cadherins in promoting insulin secretion from human β-cells was demonstrated using recombinant 
E- and N-cadherin peptides fused with Fc immunoglobulin to mimic the homophilic adhesion of 
cadherins that occurs in vivo [36].  
 
Other adhesion receptors belonging to the immunoglobulin-like cell adhesion molecules, such as N-
CAM, have also been implicated in islet function. Deletion of N-CAM in mice impairs glucose 
tolerance and reduces insulin secretion as a result of defective F-actin reorganisation [37]. Connexin 
36, ephrin-As and their EphA receptor tyrosine kinases are also involved in islet cell-cell interactions, 
where they allow rapid electrical coupling and intercellular connectivity [38–40].  
 
The therapeutic potential of cadherins is evident from the recent proposal that drugs targeting E-
cadherin re-expression may be useful in diagnosing and treating cancer [41] (Table 1). Thus, 
developments in cancer pharmacotherapy may be beneficial in the search for new treatments for 
diabetes, but a tractable cadherin target that would be clinically viable as a therapy for T2D has not 
yet been identified. 
 
Adhesion GPCRs 
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Adhesion GPCRs (aGPCRs) are the second largest group of the GPCR superfamily, with 33 human 
members identified to date [42]. Unlike the classical GPCRs, aGPCRs have complex structural 
features: they possess an unusually long extracellular N-terminal domain that is joined non-
covalently with the seven-transmembrane C-terminal domain at a GPCR proteolytic site (GPS) within 
the evolutionarily conserved GPCR autoproteolysis-inducing (GAIN) domain (Figure 1). They are the 
least studied class of the GPCR family, despite the important roles they play in many physiological 
processes [42]. 
 
Mouse and human islets express approximately 60% of all known aGPCRs [43, 44] and recent 
advances are beginning to shed light on the biological roles of aGPCRs in islets and glucose 
homeostasis. The first evidence linking aGPCRs to metabolic function was provided by studies in 
which adipose tissue-specific deletion of GPR116 led to insulin resistance and glucose intolerance 
[45] while the absence of Celsr2/3 resulted in mice with severe deficiency in β-cell differentiation 
and glucose intolerance [46]. Another interesting member of the aGPCR family is GPR56. It is the 
most abundant islet GPCR [44], and it is expressed exclusively by the β-cells in islets [5]. Activation of 
islet GPR56 by its endogenous ligand, collagen III, has beneficial effects, including potentiation of 
glucose-stimulated insulin secretion and protection of islets against the deleterious effects of 
inflammation that occur in diabetes [5, 47]. Moreover, a recent study has shown that pre-treating 
human islets with mesenchymal stromal cell-derived ECM, which is rich in the GPR56 agonist 
collagen III, led to enhanced insulin output [2]. These observations, and others indicating improved 
islet function elicited by collagen and laminin ECM components, have led to the proposal that 
exposure of human islets to ECM molecules may improve the outcomes of islet transplantation 
therapy [48]. 
 
The unique structural features of the aGPCRs present excellent opportunities for therapeutic 
targeting. They usually contain an extracellular tethered agonist-containing ‘stachel’ sequence 
buried within the GAIN domain that becomes exposed upon ligand binding or detachment of the 
extracellular domain segment, and this activates downstream signalling. Synthetic peptides that 
mimic the stachel sequence have been shown to directly activate a range of aGPCRs including GPR56, 
GPR64, GPR110, GPR114, GPR133, GPR126 and latrophilin [49–52], but the similarity of aGPCR 
stachel sequences may result in agonist promiscuity that limits the ability to specifically target 
particular aGPCRs [53]. However, receptor activation and signalling varies between different aGPCRs 
[54], suggesting that specific pathways can be selectively targeted by biased ligands. Thus, the 
possibility of using synthetic peptides to activate desirable pathways downstream of adhesion 
receptors offers a promising prospect for drug development, which may be applicable for treating 
T2D.  
  
Conclusions 
There is a large body of evidence demonstrating that signalling via integrin, cadherin and aGPCR 
adhesion receptors has beneficial effects on islet function and these receptors might serve as novel 
targets for T2D therapy. However, unless specificity can be assured increased islet integrin signalling 
is unlikely to be an appropriate therapeutic strategy since integrins are involved in tumorigenesis. E-
cadherin may be a suitable candidate for therapeutic intervention given its positive effects on islet 
function and the recent interest in development of drugs increasing expression of this cadherin for 
cancer treatment, but little progress has been made in further elucidating the role of E-cadherin in 
6 
 
islets in the past few years. The most promising adhesion receptor candidates for treating T2D are 
likely to be the aGPCRs since GPCRs are the targets of more than one-third of all prescription drugs 
in use, with GLP-1 receptor agonists being one of the most recent T2D therapies to be introduced. 
However, to date there have not been any clinical trials of aGPCR ligands. This apparent neglect 
might be a consequence of the majority of aGPCRs being orphans, and progress in this area is likely 
to be contingent on identification of the endogenous ligands.  
 
In addition to providing potential targets for T2D drug development, islet adhesion receptors offer 
translational potential in islet transplantation therapy for T1D. For example, the loss of functional 
viability reported after islet isolation could be reduced by incubating isolated islets with agonists of 
islet adhesion receptors prior to transplantation. Islet transplantation outcomes could also be 
improved by co-delivery of ECM-derived products or other agonists of islet adhesion receptors to 
improve islet survival and function. 
 
In summary, studies on the applicability of islet adhesion receptors as therapeutic entities are at a 
relatively early stage and much work is still required to identify the most appropriate receptor, 
activating ligand(s) and selectivity of effect before there is a prospect of clinical trials.  
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Figure 1: Islet adhesion receptors.  
A) Integrins are transmembrane heterodimers composed of α and β-subunits. They provide adhesion 
through interaction of the extracellular domains with ECM molecules and they also recruit 
intracellular proteins that mediate cell signalling via their short cytoplasmic domains. 
B) Adhesion GPCRs have adhesion molecules on their extracellular domain, which is joined non-
covalently to the seven-transmembrane segment at the GPCR proteolytic site (GPS) within the GPCR 
autoproteolysis-inducing (GAIN) domain. Removal of the extracellular segment above the GPS 
exposes the embedded tethered agonist, which elicits downstream signalling. 
C) Cadherins consist of five-extracellular repeats containing Ca2+ binding sites that enable them to 
participate in homophilic adhesion. The small cytoplasmic segment of cadherins regulates 
interaction with the actin cytoskeleton and intracellular signalling via binding to catenin proteins. 
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Table 1 Adhesion receptors antagonists that have been used in clinical trials.  
The table includes a non-exhaustive list of drugs developed by a range of pharmaceutical companies 
that target adhesion receptors for clinical use. It also includes information on the highest 
development phase of clinical testing for each drug, or whether the drug is in current clinical use. 
Information was obtained from clinicaltrials.gov. 
 
Drug Adhesion 
receptor 
Disease targets Clinical 
trials 
status 
Company 
Anti-
Integrins 
PF-04605412 
 
Volociximab 
 
 
MEDI-522 
 
 
Ro 27-2441 
 
Natalizumab 
 
Vedolizumab 
 
 
Anti-
cadherin 
ADH-1 
 
 
 
α5β1 
 
α5β1 
 
 
α5β3 
 
 
α4β1 
 
α4β1 
 
α4β7 
 
 
 
 
N-cadherin 
 
 
 
 
Advanced non-hematologic malignancies 
 
Renal cell carcinoma, age-related macular 
degeneration 
 
Rheumatoid arthritis, metastatic 
melanoma, prostate cancer 
 
Asthma 
 
Multiple sclerosis 
 
Ulcerative colitis, Crohn’s disease 
 
 
 
 
Neoplasm 
 
 
Phase I 
 
Phase II 
 
 
Phase II 
 
 
Phase II 
 
Clinical use 
 
Clinical use 
 
 
 
 
Phase I 
 
 
Pfizer 
 
PDL 
Biopharma 
 
MedImmune 
 
 
Roche 
 
Biogen 
 
Millennium 
Pharmaceut. 
 
 
 
Adherex 
Tech 
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Table 2 A summary of adhesion receptors expressed by islets and their effects on islet function.  
The table summarises the adhesion receptor family members that have been identified in islets and 
provides information, where available, on the native ligand(s), signalling pathways downstream of 
receptor activation and effects on islet function. 
 
Adhesion 
receptor 
Expression by 
islets 
Ligand/binding 
partners 
Signalling 
pathways 
Effect of receptor activation 
on islet functions 
Integrins α1β1 
 
α3β1 
α5β1 
αvβ1 
α6β1 
Collagen IV 
 
Unknown 
Unknown 
Unknown 
Laminin-5 
FAK, ERK 
 
Unknown 
Unknown 
Unknown 
Unknown 
 insulin secretion, islet 
architecture [55] 
Unknown 
Unknown 
Unknown 
 insulin secretion [4] 
Cadherins E-cadherin 
N-cadherin 
Homophilic 
interactions 
Catenins, 
F-actin 
 -cell apoptosis [32],  
insulin secretion [36] 
Adhesion 
GPCRs 
ADGRG1 (GPR56) 
 
ADGRF5 (GPR116) 
 
ADGRG3 (GPR97) 
ADGRG6 (GPR126) 
ADGRL1 (LPHN1) 
 
 
ADGRL2 (LPHN2) 
ADGRL4 (ELTD1) 
ADGRA3 (GPR125) 
ADGRD1 (GPR133) 
ADGRC2 (CELSR2) 
ADGRC3 (CELSR3) 
Collagen III, 
TG2 
Surfactant 
protein 
Unknown 
Collagen IV 
α-latrotoxin, 
neurexins and 
tenuerins 
Tenuerins 
Unknown 
Unknown 
Unknown 
Unknown 
Unknown 
Gα12/13, Gαq 
 
Gαq 
 
Gαo, RhoA 
Gαs  
Gαo 
 
 
Unknown 
Unknown 
Unknown 
Gαs, cAMP 
Ca2+ 
Ca2+ 
 insulin secretion,  β-cell 
apoptosis [5, 47]  
Unknown 
 
Unknown 
Unknown 
Unknown 
 
 
Unknown 
Unknown 
Unknown 
Unknown 
Unknown 
Unknown 
 
  
 
